doi:10.3969/j.issn.1673-8640.2016.03.020

Abstract

CLC Number:

R446.1

Figures/Tables 2

References 12

1	ROSENFELD H,ORNOY A,SHECHTMAN S,et al.Pregnancy outcome,thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil:a controlled cohort study[J].Br J Clin Pharmacol,2009,68(4):609-617.
2	顾金萍,宋梦帆,范建霞. 妊娠期甲状腺功能减退对妊娠结局和子代的影响[J].中华围产医学杂志,2011,14(6):374-378.
3	中华医学会内分泌学分会,中华医学会围产医学分会.妊娠和产后甲状腺疾病诊治指南[J]. 中华内分泌代谢杂志,2012,28(5):354-371.
4	叶任高,陆再英. 内科学[M]. 6版.北京:人民卫生出版社,2005:729-737.
5	柯文才,顾芸霞.不同妊娠期孕妇甲状腺激素水平的研究分析[J]. 检验医学,2015,30(3):224-226.
6	贾慧思,盖铭英.妊娠合并甲状腺功能减退[J]. 实用妇科杂志,2006,22(10):580-581.
7	LI Y, SHAN Z, TENG W, et al.Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months[J]. Clin Endocrinol(Oxf), 2010, 72(6):825-829.
8	薛海波,李元宾,滕卫平,等.妊娠早期母亲亚临床甲状腺功能减退症对其后代脑发育影响的前瞻性研究[J]. 中华内分泌代谢杂志,2010,26(11):916-920.
9	刘迪杰,单忠艳,滕卫平,等.妊娠期亚临床甲减大鼠对子代学习记忆能力及脑发育相关基因表达的影响[J].中华内分泌代谢杂志,2010,26(11):936-941.
10	董丽,孙丽芳.甲状腺自身抗体和促甲状腺素预测流产的价值[J].中国妇产科临床杂志,2011,12(3):191-193.
11	单忠艳,滕卫平.倡导妊娠期甲状腺疾病筛查,保护后代智力发育[J]. 中华内分泌代谢杂志,2010,26(11):913-915.
12	DEMERS LM,SPENCER CA.Laboratory medicine practice guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease[J]. Clin Endocrinol(Oxf),2003,58(2):138-140.

组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	甲状腺功能异常
组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	合计（例）	异常率（%）
妊娠早期组	269	0	16	2	0	18	6.69
妊娠中期组	562	2	40	0	2	44	7.83
妊娠晚期组	716	3	54	2	1	60	8.38
合计	1 547	5	110	4	3	122	7.89

组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	甲状腺功能异常
组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	合计（例）	异常率（%）
妊娠早期组	269	0	16	2	0	18	6.69
妊娠中期组	562	2	40	0	2	44	7.83
妊娠晚期组	716	3	54	2	1	60	8.38
合计	1 547	5	110	4	3	122	7.89

组别	例数	FT4（pmol/L）	TSH（mIU/L）
妊娠早期组	269	15.99±2.16^*	1.29±0.41^*
妊娠中期组	562	14.11±2.24^*#	1.98±0.39^*#
妊娠晚期组	716	12.14±2.10^*#▲	2.36±0.32^*#▲
正常对照组	60	16.87±3.16	3.46±0.88

组别	例数	FT4（pmol/L）	TSH（mIU/L）
妊娠早期组	269	15.99±2.16^*	1.29±0.41^*
妊娠中期组	562	14.11±2.24^*#	1.98±0.39^*#
妊娠晚期组	716	12.14±2.10^*#▲	2.36±0.32^*#▲
正常对照组	60	16.87±3.16	3.46±0.88

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 12

Related Articles 15

Recommended Articles

Metrics